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ABSTRACT
Mecwan, Marvin Magan. MS. The University of Memphis. December 2011.
Design and Evaluation of a Novel Composite Chitosan-Poly(Lactide-co-Glycolide)
Microsphere Based System for Bone Tissue Engineering Applications. Major Professor:
Joel D. Bumgardner, Ph.D.
Nearly 60% to 67% of all injuries that occur annually within the US are due to
musculoskeletal injuries, with over a million people requiring implants and bone grafting
materials to reconstruct bone defects. Our lab has previously developed composite
chitosan/nano-hydroxyapatite microsphere based bone grafts that had good compressive
strengths, supported bone cell growth and mineralization in vitro, demonstrated
biocompatibility and osteoconductivity in a rat calvarial defect model, and when loaded
with rhBMP-2 was osteoinductive in a rat muscle pouch model. However, degradation of
these scaffolds was very slow which may have limited the amount of new bone formed in
vivo. The objectives of this research was to develop a novel composite Chitosan-PLGA
microsphere based system prepared via a precipitation method with improved
degradation and biological characteristics as compared to plain chitosan (CTS)
microspheres. The effect of varying PLGA amounts within the CTS microspheres was
evaluated via degradation and biocompatibility studies in addition to physiochemical
properties. PLGA particles in the composite CTS-PLGA microspheres segregated to the
surface of the microspheres resulting in roughened surface textures. In addition,
composite microspheres also had reduced crystallinity resulting in reduced exothermic
peak temperatures as seen from XRD and DSC studies; showed increased degradation
and better osteoblast attachment as compared to plain CTS microspheres. However, no
effect was seen on osteoblast proliferation over a 7 day cell culture period. The results of
this study showed that composite CTS-PLGA microsphere based systems have the
potential to be used in bone tissue engineering applications and future studies will be
aimed at evaluating its potential as a dual drug delivery vehicle.
iv

PREFACE
The main body of this thesis is a journal article entitled, ―Design and Evaluation
of a Novel Composite Chitosan-Poly(Lactide-co-Glycolide) Microsphere Based System
for Bone Tissue Engineering: Preliminary Degradation and Biocompatibility Studies.‖
This manuscript will be submitted to the Journal of Biomedical Materials Research Part
B: Applied Biomaterials.
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CHAPTER 1: INTRODUCTION

1.1

Statement of Clinical Problem
Nearly 60% to 67% of all injuries that occur annually within the United States are

due to musculoskeletal injuries, with upper and lower extremity fracture cases averaging
around 12.5 million every year between 1998 and 2004.1 Of these, over a million people
require implants and bone grafting materials to reconstruct bone defects from disease or
trauma each year,2 costing between $34,000 to $37,000 per procedure.3 Autografts
remain the ―gold standard‖ for stimulating bone growth and regeneration owing to its
osteoconductive, osteoinductive and osteogenic properties.4-6 Allografts, on the other
hand, possess the same properties as autografts but with lesser osteoinductive and
osteogenic properties.7,8 These bone graft substitutes, however, are limited in their use
due to their availability and complications such as tissue morbidity, immunological
rejection and disease transmission that are associated with them.4,6,8-10 As a result of the
limitations surrounding the use of autografts and allografts as bone graft substitutes, there
is a pressing clinical need for the development of biologically active bone graft
substitutes that can be used to treat non-union musculoskeletal injuries.6-8
Our lab has previously developed chitosan-based materials in the form of films,1113

sponges 14 and microsphere 15-17 for various tissue engineering and drug delivery

applications. In particular, our chitosan-based microsphere constructs for use as a bone
graft substitute material for bone tissue engineering and local drug delivery have been
prepared by a novel precipitation method.15-17 These microspheres are then fabricated
into three-dimensional constructs to mimic the porous architecture of cancellous bone.
Research has shown that these constructs have proven to have good compatibility with
1

osteoblasts and have demonstrated to have mechanical properties and porosity sufficient
to support new bone growth in vitro as well as in vivo.15,16 Furthermore, these
microspheres can be loaded with desired proteins and growth factors such as BMP-2 to
enhance their osteoconductivity and promote bone growth.17 However, in vitro and in
vivo studies have shown that chitosan-based microsphere bone graft constructs exhibit a
slow degradation profile.15-17 A slow degradation profile could potentially limit the
continuous production and/or retard growth of bone within the chitosan scaffold and the
defect area;18 therefore limiting the use of chitosan as a bone graft for bone tissue
engineering applications. Hence, an improvement in the degradation profile of the
chitosan microsphere-based bone graft material is needed to further optimize and
improve the desirable properties and characteristics of the scaffold design for bone tissue
engineering and local drug delivery applications.

1.2

Hypothesis and Objectives
According to Roberts, it takes around 18 weeks in humans for the reparative

phase of bone healing and up to 54 weeks for the remodeling phase19 and maturation of
bone.20 Based on this, ideally, we would prefer a bone scaffold that degrades without
losing its mechanical strength within the first 4-6 months which would provide the much
needed initial support, followed by complete degradation within the year which would
allow space for native bone to regenerate and grow. In this work, our strategy is to
develop a composite system with chitosan and poly(lactide-co-glycolide) so that we can
tailor the degradation profile of chitosan to match our desired goal, while maintaining its
osteoconductive and osteoinductive properties.

2

We hypothesize that the incorporation of 50:50 poly(lactide-co-glycolide) or
PLGA into chitosan microspheres by a precipitation method increases the
degradation rate of the chitosan microspheres. Furthermore, we hypothesize that
incorporating 50:50 PLGA into chitosan microspheres will have no effect on
compatibility of microspheres with osteoblasts.
The rationale behind this hypothesis is that chitosan is known to have immense
potential as an orthopaedic biomaterial21-27 but chitosan based 3D scaffolds have very low
degradation rates which could limits its use in tissue engineering and drug delivery
applications. Furthermore, chitosan is known to degrade in acidic conditions28,29 and
50:50 PLGA is known to degrade rapidly, releasing acidic by-products 30-32 which could
potentially drive the degradation of chitosan.

1.2.1

Objectives
To test these hypotheses, the following specific objectives were undertaken:

Objective I
Prepare and characterize composite Chitosan-PLGA microspheres.
a) Prepare PLGA particles via an emulsion-diffusion-evaporation technique.
b) Incorporate PLGA particles into chitosan microspheres (25 wt% and 50 wt%)
via a precipitation method.
c) Determine the amount of PLGA within the composite Chitosan-PLGA
microspheres.
d) Characterize the composite Chitosan-PLGA microspheres for amount of
PLGA using confocal imaging; for shape and surface morphology using

3

digital microscopy; for crystallinity via x-ray diffraction spectrometry; and
thermal degradation properties via differential scanning calorimetry.

Objective II
Characterize the degradation profile of composite Chitosan-PLGA microspheres
over a two month period in a lysozyme solution.
a) Determine the change in mass of the composite microspheres over the two
month period as compared to plain chitosan microspheres.
b) Evaluate the change in surface topography in the composite microspheres
using digital microscopy.

Objective III
Evaluate the ability of human osteosarcoma bone cells (Saos-2) to attach and
proliferate on the composite Chitosan-PLGA microspheres over a week.
a) Determine the percent cell attachment on the surface of the composite
microspheres as compared to plain chitosan microspheres.
b) Determine the proliferation of cells on the surface of the composite
microspheres quantitatively as well as qualitatively as compared to plain
chitosan microspheres.

1.2.2

Significance
We propose preparing composite Chitosan-PLGA microspheres using a unique

method of incorporating PLGA particles within chitosan microspheres via a precipitation
method. The incorporation of PLGA would help increase the degradation rate of chitosan
scaffolds without losing mechanical strength. As the PLGA particles degrade, the acidic
4

by-products produced will help drive the degradation of chitosan, providing a means for
increasing and subsequently optimizing the overall degradation rate of the composite
Chitosan-PLGA microspheres. This research is significant as the results would provide
data on the potential of using a composite Chitosan-PLGA microsphere system as a bone
graft material for bone tissue engineering applications for the treatment of bone fractures
and defects.

5

CHAPTER 2: LITERATURE REVIEW
2.1

Bone injury and repair
It has been reported that nearly six million bone fractures occur every year in the

United States alone.19 A fracture is usually caused by the inability of bone to withstand
an applied external force. When bone is injured or fractured, it has the inherent
physiological property and response mechanisms to heal, repair and model itself back to
its pre-injured condition. The complexity and pattern of the fracture decides the healing
process associated with it.
Usually, bone healing follows three important and distinct phases: the early
inflammatory phase, the reparative phase, and the late remodeling phase.33-36 The first
phase of the bone healing process begins with the formation of a blood clot or hematoma
at the fracture site which works to stabilize the fracture. The cocktail of inflammatory
cytokines and chemokines produced in response to the fracture results in the recruitment
and migration of macrophages, fibroblasts, osteoblasts, mesenchymal stem cells (MSCs)
and vascular stem cells to the fracture site which initiates the bone healing process. This
is then followed by the reparative phase of bone healing during which a soft callous of
cartilage is produced around the fracture site by chondrocytes which is then mineralized
by osteoblasts creating a hard callous of woven bone. At this point during the healing
process, the bone structure is disorganized and as a result very weak and prone to refracture. Remodeling of this weak woven bone into more organized lamellar bone is
necessary and occurs during the final remodeling phase of the bone healing process.
Osteoclasts and osteoblasts work together at this stage to remodel woven bone into
lamellar bone and restore the bone to its pre-injured state, shape and strength.33,37-42 It
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takes around 18 weeks in humans for the reparative phase of bone healing to take place,
which includes the formation of a woven callus and lamellar compaction. This is
followed by ―interface remodeling and compacta maturation of the bone‖ which occurs at
54 weeks 53.
The above described healing process works well for simple fractures. However,
for more complex fractures and defects that disrupt bone-to-bone interaction, normal
physiological bone healing is inhibited resulting in delayed or non-union bone
fractures43—these fractures generally lead to scarring rather than regeneration.44 These
fractures are a result of complex musculoskeletal trauma, failing to heal even after several
months of occurrence.45 They are associated with a number of risk factors such as softtissue injury, physiological compromise, extensive bone loss, fracture instability and
infection.46
There is not much research done on what the critical size bone defect is in
humans, but usually a defect > 1cm is often considered to be a critical size defect.47 A
number of animal studies in larger animals such as sheep use long bone critical size
defect models of 2.5 cm,48 3cm,49 or 3.2cm.50 Usually, non-union treatments with critical
size bone defects involve surgical intervention such as bone graft implantation in
conjunction with internal fixation is required in addition to long-lasting therapies to
restore bone continuity and stability.7,51

2.2

Bone grafts
Bone grafts are used to repair complex bone fractures in cases of complex

musculoskeletal trauma that pose potential health risks to the patient and fail to heal after
several months. According to Glassman and coworkers, bone graft procedures range
7

from approximately $33,860 to $37,227 and includes but is not limited to the actual cost
of the bone graft, surgeon and anesthesiologist fees, hospital charges, medication charges
as well as additional fees for services such as medical supplies, diagnostic procedures and
equipment use fees.3 In the United States alone, over 500,000 bone grafting procedures
have been performed and it is estimated that with the increase in age-related fractures the
number of procedures performed by the year 2020 will reach 51.5 million.52,53
Bone grafts help to bridge the gap between bones at the fracture site and serve as
a temporary support with some mechanical integrity and a favorable environment for
osteogenesis, osteoconduction, and possible osteoinduction—important properties
required for bone healing and remodeling. Bone grafts are usually implanted in
conjunction with either an internal or external fixation device to provide for additional
mechanical support while the bone heals and remodels, restoring bone continuity at the
fracture site.
The most common types of bone grafts currently used are autografts and
allografts. Despite their many advantages with regard to their osteoconductivity,
osteoinductivity and possible osteogenicity, these bone grafts are known to have their
disadvantages too which have caused researchers to explore other alternatives, such as
synthetic bone grafts.

2.2.1

Autografts
Autografts remain the ―gold standard‖ for stimulating bone growth and

regeneration owing to its osteoconductive, osteoinductive and osteogenic properties.4-6
Autografts are commonly defined as tissues grafted from one part of an individual to
another part of the same individual. Bone autografts are generally extracted from the
8

iliac crest, the fibula, the mandible and even parts of the skull of the patient. The surgical
procedure involving the harvesting of autologous bone graft, however, is associated with
a number of complications for the patient including tissue morbidity, nerve and muscle
damage, chronic pain as well as infection.6,54-58 Furthermore, there is limited availability
of the size, shape and quantity of such bone grafts which limit their use clinically.6-8

2.2.2

Allografts
Allografts offer an alternative approach for the treatment of non-union bone

fractures with the same characteristics as autografts but they lack osteogenic properties
due to the absence of viable osteogenic cells.6,8 Allografts are defined as tissues grafted
from one individual to another individual and are usually obtained from cadavers. Bone
allografts are often used either as fresh or fresh-frozen bone, freeze-dried bone allografts,
or demineralized freeze-dried bone allografts. Some advantages of allografts over
autografts are its availability in different shapes and sizes and no donor site tissue
morbidity.6 However, there are complications associated with allografts and include
disease transmission and immunogenicity.6,8,10

2.2.3

Synthetic bone grafts
Currently, much research is directed towards the development of synthetic bone

graft substitutes in order to obviate the limitation regarding autografts and allografts for
the treatment of non-union bone fractures. Bone tissue engineering approaches focus on
the use of synthetic scaffolds that mimic the physical and mechanical nature of bone
while inducing bone healing through the use of growth factors, preventing infection with
the use of antibiotics and providing an environmentally favorable matrix for cells to grow
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and proliferate for new bone formation.5 For this purpose, ideally, synthetic bone grafts
should be biocompatible, porous in structure to allow for cellular infiltration and
vascularization, osteoconductive, osteoinductive, biodegradable, have similar mechanical
properties as bone, undergo remodeling and support generation of new bone.5,8,59,60.
From an engineering perspective, synthetic bone graft scaffolds for bone tissue
engineering should meet the following requirements: 1) Three-dimensional
architecture—possess interconnecting pores of appropriate size to promote tissue
integration and vascularization, 2) Biocompatibility—not elicit an immune response that
would cause the host to reject the bone graft, 3) Osteoconductivity—provide a matrix
upon which osteoblasts can proliferate and generate new bone, 4) Osteoinductivity—
stimulate osteoprogenitor cells to differentiate into bone forming cells or osteoblasts, 5)
Biodegradable—possess a controlled degradation rate so that native tissue will gradually
replace the bone graft, 6) Biomechanics—have adequate mechanical properties to match
cancellous bone or the intended site of implantation, and 7) be easy to manufacture,
sterilize and handle in the operating room.19,26

2.3

Biomaterials used in bone tissue engineering applications
All criteria for an ideal synthetic bone graft for bone tissue engineering

applications cannot be achieved without the use of a biomaterial. Hence, large emphasis
is put on choosing the right biomaterials for use as a synthetic bone graft as biomaterials
are an essential part of tissue engineering strategies. However, fabricating a bone
scaffold with all the essential requirements poses a significant challenge for researchers
and therefore a lot of research is being done to better understand biomaterials so that
ideal bone graft scaffolds can be fabricated and engineered.
10

The most common type of biomaterials used as bone grafts for bone tissue
engineering applications are ceramics, polymers, or a composite of ceramics and
polymers. Both ceramics and polymers can be either resorbable or non-resorbable, and
polymers can be either naturally derived or derived from synthetic sources. 61 These
biomaterials can be constructed into three-dimensional structures that are
osteoconductive, osteoinductive and with sufficient mechanical integrity, making them
suitable as bone graft scaffolds for bone healing and remodeling. Each of these
biomaterials comes with their set of pros and cons, and biomaterial researchers have been
trying to manipulate these materials so that their advantages can be maximized and their
disadvantages minimized.

2.3.1

Ceramics
Ceramics are inorganic and nonmetallic substances known for their high

compressive strengths. They have been used over the years in a variety of dental and
orthopaedic applications because of their similarity to the mineral phase of bone—
making them osteoconductive—and due to their ability to form direct bonds with the
surrounding bone.61 The most commonly studied ceramics for use as bone graft scaffolds
include calcium carbonates, calcium sulfates, calcium phosphates and bioactive glass.
Ceramics are desired because they are biocompatible and elicit minimal immunological
and foreign body reactions due to the lack of proteins associated with them.61 Most
ceramics, however, are not osteoinductive.61 Furthermore, ceramics have a high
resistance to deformation causing it to be brittle and they are also difficult to machine
into complex shapes and porous constructs.62

11

2.3.2

Polymers
Polymers used as bone graft substitutes for bone tissue engineering applications

can be either derived from natural sources—polysaccharides such as alginate, chitin,
chitosan and hyaluronic acid, or proteins such as collagen, fibrin and silk—or from
synthetic sources such as poly(lactic acid), poly(glycolic acid), poly(lactide-coglycolide), poly(ε-caprolactone) and poly(hydroxyl butyrate). Naturally derived
polymers are known to support cell attachment but have poor mechanical strength and are
limited in supply, making them costly.63 On the other hand, synthetic polymers have
relatively good mechanical strength, tunable degradation rates and can be manipulated
into desired shapes, but lack moieties that support cell adhesion.63 However, it should be
noted that some synthetic polymers have undesirable acidic degradation products and low
cellular compatibility, whereas natural polymers have limited degradation and lower
mechanical strengths compared to ceramics.64

2.3.3

Composites
Composite systems are often prepared to utilize the advantageous properties of

two or more materials involved while reducing their disadvantages. For example,
polymer composites with ceramics have been formulated and investigated as bone tissue
engineering constructs to increase the mechanical strength of the polymer while retaining
the osteoconductive and biodegradative properties of the polymer.
Chesnutt et al. prepared a novel chitosan/nano-hydroxyapatite composite bone
scaffold using a co-precipitation method.15 The results of their study showed that the
addition of hydroxyapatite to chitosan resulted in an increase in surface roughness and
area of the scaffolds, increase in compressive modulus of the scaffolds (nearly 300%
12

increase), and had increased osteoblast proliferation as compared to chitosan scaffolds,
hence making it a better bone graft material.15
Wu et al. used a similar strategy, wherein they used composite PLGA scaffolds to
make them better suited as tissue regeneration scaffolds.65 They prepared PLGA
scaffolds and coated them with collagen, chitosan or N-succinyl-chitosan. The results of
their study showed that PLGA scaffolds coated with collagen had increased cellular
attachment and proliferation as compared to PLGA scaffolds alone.65 Furthermore, their
study showed that PLGA scaffolds coated with chitosan had reduced degradation rates
and resulted in greater differentiation of osteoblastic stromal cells based on alkaline
phosphatase activity as compared to PLGA scaffolds alone.65 By coating a synthetic
polymer with naturally derived materials, Wu and coworkers were able to modify the
microenvironments of PLGA scaffolds making them osteoconductive and osteoinductive,
and hence suitable for tissue engineering applications.

2.4

Chitosan
Chitosan, a partially N-deacetylated derivative of chitin, a natural polysaccharide

derived from the exoskeleton of crustaceans. It has shown to have immense potential as
an orthopaedic biomaterial with many attractive properties—osteoconductivity,
biocompatibility, non-toxic and non-acidic degradative products, formable into threedimensional (3D) scaffolds—making it an ideal candidate for bone tissue engineering and
drug delivery applications.21-27
Chitosan can easily be formed into microspheres to make bone scaffolds with
good mechanical strength and porosity to support bone cell in-growth 15,16 and as an
efficient drug and protein delivery vehicle.17,66 Despite its many appealing properties for
13

bone growth and regeneration and its use as a therapeutic agent delivery protein delivery
vehicle, biodegradation rate of chitosan microsphere-based scaffolds has been very low.
A slow degradation profile could potentially limit the continuous production or even
retard growth of bone within the chitosan scaffold and the defect area;18 therefore
limiting the use of chitosan as a bone graft for bone tissue engineering and drug delivery
applications.
Degree of deacetylation and molecular weight are two important properties of
chitosan and are known to affect its physicochemical and biological properties. It has
been reported that biodegradation of chitosan increases with decrease in degree of
deacetylation of chitosan 67,68 as well as with decrease in molecular weight of the
polymer.69,70 Thus, choosing chitosan with a lower degree of deacetylation and
molecular weight could be one possible route for increasing the polymer’s degradation
rate.
Conversely, it has also been reported that mechanical strength of chitosan
decreases with the decrease in the degree of deacetylation71,72 and molecular weight of
chitosan.73 It is imperative that chitosan scaffolds for bone tissue engineering
applications would need to possess mechanical strength while being able to degrade.
Hence, lowering the degree of deacetylation and molecular weight to increase
biodegradation of the polymer is not the best choice and alternate routes need to be
explored.

2.5

Poly(lactide-co-glycolide)
One alternative is to use chitosan in conjunction with the co-polymer poly(lactide-

co-glycolide) or PLGA which is part of the family of poly(α-esters). Other members of
14

the family of poly(α-esters) include poly(glycolic acid) (PGA) and poly(lactic acid)
(PLA). PGA is a highly crystalline polymer and exhibits a high tensile modulus and high
rate of degradation.74 PLA, on the other hand, is also crystalline and is a slow degrading
polymer compared to PGA and has good tensile strength and a high modulus.74
PLGA, a synthetic co-polymer of lactic acid and glycolic acid, forms amorphous
polymers.74 It is known for its biocompatibility, biodegradability and mechanical
strength.30-32,75 PLGA is known to degrade via hydrolysis releasing the original
monomers—both of which are acidic.30-32 The 50:50 PLGA is very unstable and
degrades in approximately 1-2 months.74 Furthermore, PLGA nanoparticles have been
extensively studied as drug delivery vehicles of anti-inflammatory drugs,76 anti-cancerous
drugs,76,77 antibiotics,78 anti-diabetic agents,79 and hormones 80 to name a few.

2.6

Composite Chitosan-PLGA materials
A number of research labs in the recent years have formulated composite

chitosan-PLGA systems for bone tissue engineering applications in a variety of forms
such as fiber meshes,81 scaffolds 82 and microspheres.83,84 The inspiration behind
formulating composite systems for bone tissue engineering applications such as one with
chitosan and PLGA is to take advantage of the biocompatibility and osteoconductive
properties of chitosan and mesh it with the mechanical strength, tailorable degradation
and drug delivery properties of PLGA, creating a superior bone graft scaffold material
that is better than chitosan or PLGA alone.
For example, Yilgor and coworkers have reported making PLGA nanocapsules
loaded with BMP-2 or BSA which were then loaded either within or onto chitosan 3D
mesh fiber scaffolds.81 The PLGA nanospheres were loaded with bone morphogenetic
15

protein-2 (BMP-2) or bovine serum albumin (BSA) by a double emulsion-solvent
evaporation technique. The chitosan 3D mesh fibers were prepared by a wet-spinning
method. In order to incorporate the PLGA nanocapsules within the chitosan fiber mesh,
the nanocapsules were mixed with the chitosan solution before the wet-spinning
process.81 On the other hand, to incorporate the PLGA nanocapsules on the chitosan
fiber mesh, 100μL of nanocapsules solution was applied to either side of the wet-spun
chitosan fiber mesh, applied through a series of vacuum-pressure cycles, and dried
overnight in a vacuum.81 Yilgor et al. reported that the chitosan fiber meshes with PLGA
nanocapsules containing BMP-2 were better at differentiating bone marrow MSCs, based
on the increased alkaline phosphatase (ALP) activity of the cells, as compared to PLGA
nanocapsules alone.81 Furthermore, they claimed that drug delivery was better in the
system where the nanocapsules were attached onto the chitosan fiber mesh as compared
to the system where the nanocapsules were within the chitosan fiber mesh.81 They
suggest that sequential growth factor delivery via these nanocapsules on chitosan fiber
meshes would be a better approach in bone tissue engineering applications than
individual growth factor delivery as it would mimic the natural process of bone healing.81
Recently, Nandagiri et al. prepared porous chitosan-gelatin scaffolds (chitosangelatin in a 1:2 ratio by weight) embedded with various amounts of BSA loaded PLGA
nanoparticles.82 BSA loaded PLGA nanoparticles were also prepared by a double
emulsion-solvent diffusion method. The chitosan-gelatin scaffolds crosslinked with
genipin were prepared by lyophilization. PLGA nanoparticles were embedded within
these chitosan-gelatin scaffolds by dispersing an aqueous suspension of PLGA
nanoparticles into the chitosan-gelatin solution at different weight concentrations (16.6%,
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33.3% and 66.6% respect to chitosan-gelatin weight), followed by crosslinking with
genipin and then undergoing a lyophilization process to prepare sponge scaffolds.82
Nandagiri et al. reported that the addition of PLGA nanoparticles to the chitosan-gelatin
scaffolds modulated physical and mechanical properties of the chitosan-gelatin
scaffolds.82 In particular, increasing PLGA wt% within the chitosan-gelatin scaffolds
resulted in a decrease in water uptake, increase in compressive modulus and an increase
in dissolution over a ten day period.82 However, there was no effect of PLGA wt%
concentration on the attachment and proliferation of clonal human osteoblast cell line
(hFOB) over an eleven day period on the chitosan-gelatin scaffolds.82 Interestingly, the
authors claimed that the delivery of BSA from the PLGA nanoparticles was prevented
―by properly selecting the pH of the external aqueous phase‖ and ―by increasing its
osmolality by adding sodium chloride‖—no BSA delivery data was reported. They
concluded that the 33wt% PLGA within chitosan-gelatin scaffold formulation had the
best mechanical properties (~50KPa) and retained desirable physical and cell attachment
properties as compared to the other formulations, and future studies will study the
encapsulation and release of therapeutic proteins such as BMP-2 and parathyroid
hormone (PTH) from this optimized formulation.82
Jiang et al. have reported making chitosan/PLGA sintered microsphere scaffolds
using the solvent-evaporation technique.83,84 Briefly, chitosan particles were mixed with
20% w/v PLGA solution in methylene chloride. The mixture was vortexed and
subsequently poured into 1% polyvinyl alcohol solution under constant stirring to allow
the methylene chloride to evaporate. The resultant particles were washed with DI water,
filtered, lyophilized, sieved to different sizes and stored in a dessicator for further use.
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They claimed that their chitosan/PLGA sintered microspheres had compressive modulus
and compressive strain within the range of human trabecular bone making them suitable
as scaffolds for load-bearing bone tissue engineering applications.83 They also reported
that the composite chitosan/PLGA sintered microsphere scaffolds had better
biocompatibility to MC3T3-E1 osteoblast-like cells as compared to PLGA scaffolds
alone.83 Furthermore, they suggest that the presence of chitosan in the composite
scaffolds resulted in an increase in alkaline phosphotase activity of the cells cultured on
the composite microspheres as well as up-regulated the gene expression of alkaline
phosphatase, ostepontin and bone sialoprotein.83 In a follow up paper, they reported that
over a 12 week degradation period, the compressive strain and compressive modulus of
the composite scaffolds remained in the range of human trabecular bone.84

2.7

Summary
These studies outline the benefits of using composite chitosan-PLGA materials.

As summarized, these composite materials exhibited biocompatibility and
osteoconductivity with osteoblast-like cells due to increased alkaline phosphatase activity
of the cells, and had compressive strains and compressive modulus in the range of human
trabecular bone. In these studies, essentially, the biocompatibility and osteoconductive
properties of chitosan were meshed with the mechanical strength, tailorable degradation
and drug delivery properties of PLGA. We hope to adopt a similar strategy by preparing
composite CTS-PLGA microspheres using a unique method of incorporating 50:50
PLGA particles within chitosan microspheres via a precipitation method. The
incorporation of PLGA particles would help increase the degradation rate of chitosan
scaffolds without compromising the overall mechanical strength. As the PLGA degrades,
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the acidic by-products produced will be able to help drive the degradation of chitosan,
providing a means for increasing and subsequently optimizing the overall degradation
rate of the composite CTS-PLGA microspheres. Thus, this research would provide data
on the potential of using a composite CTS-PLGA microsphere system prepared via a
precipitation method as a bone graft material for bone tissue engineering applications for
the treatment of bone fractures and defects.
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CHAPTER 3: PLANNED SUBMISSION TO JOURNAL OF BIOMEDICAL
MATERIALS RESEARCH PART B
DESIGN AND EVALUATION OF A NOVEL CHITOSAN-POLY(LACTIDE-COGLYCOLIDE) MICROSPHERE BASED SYSTEM FOR BONE TISSUE
ENGINEERING: PRELIMINARY DEGRADATION AND BIOCOMPATIBILITY
STUDIES
Abstract
Our research group has previously researched composite chitosan/nanohydroxyapatite microsphere based bone grafts that had favorable mechanical and
osteoconductive properties as a bone graft substitute. However, degradation of these
scaffolds was very slow which limited the amount of new bone formed in vivo. The
objectives of this research was to develop a novel composite Chitosan-PLGA
microsphere based system prepared via a precipitation method with improved
degradation and biological characteristics as compared to plain chitosan (CTS)
microspheres. Three different formulations of composite CTS-PLGA microspheres were
prepared: a) CP0 (100wt% CTS, 0wt% PLGA); b) CP25 (75wt% CTS, 25wt% PLGA);
and c) CP50 (50wt% CTS, 50wt% PLGA). The effect of varying PLGA amounts within
the CTS microspheres was evaluated via degradation and biocompatibility studies in
addition to physiochemical properties. PLGA was incorporated within the composite
microspheres—7.5wt% for CP25 and 12.6wt% for CP50. Digital and confocal imaging
suggested that PLGA particles in the composite CTS-PLGA microspheres segregated to
the surface of the microspheres resulting in roughened surface textures. XRD analysis
showed that the addition of PLGA resulted in reduced crystallinity which was reflected in
the reduced exothermic peak temperatures in DSC. CP25 had the highest percent weight
loss (28.2% ± 1.4%); while CP0 had the lowest percent weight loss (25.2% ± 0.3%) at the
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end of the 28 day degradation period. Highest percent osteoblast attachment was seen for
CP25 (35.3% ± 5.5%), followed by CP50 (30.2% ± 4.3%) and CP0 (23.1% ± 7.7%);
however, no effect was seen on osteoblast proliferation over a 7 day cell culture period.
These results show that composite CTS-PLGA microsphere based systems have the
potential to be used in bone tissue engineering applications and future studies will be
aimed at evaluating its potential as a dual drug delivery vehicle.
Keywords: chitosan, PLGA, composite chitosan microspheres, degradation, osteoblast
cell culture

Introduction
Nearly 60% to 67% of all injuries that occur annually within the United States are
related to musculoskeletal injuries, with upper and lower extremity fractures cases
averaging around 12.5 million every year between 1998 and 2004.1 Of these, over a
million people require implants and bone grafting materials to reconstruct bone defects
from disease or trauma each year,2 costing between $34,000 to $37,000 per procedure.3
Autografts remain the ―gold standard‖ for stimulating bone growth and regeneration
owing to its osteoconductive, osteoinductive and osteogenic properties.4-6 Allografts, on
the other hand, possess the same properties as autografts but with lesser osteoinductive
and osteogenic properties.7,8 These bone graft substitutes, however, are limited in their
use due to their availability and complications such as tissue morbidity, immunological
rejection and disease transmission that are associated with them.4,6,8-10 As a result of the
limitations surrounding the use of autografts and allografts as bone graft substitutes, there
arises a clinical need for the development of bone graft substitute materials that can be
used to treat non-union musculoskeletal injuries.6-8
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A promising material for developing bone graft substitutes is chitosan. Chitosan
(CTS) is a partially N-deacetylated derivative of chitin, a natural polysaccharide derived
principally from exoskeleton of crustaceans. CTS exhibits many attractive properties—
osteoconductivity, biocompatibility, non-toxic and non-acidic degradative products,
formable into three-dimensional (3D) scaffolds—making it a good candidate for bone
graft substitute applications.21-27 For example, Bhat et al. reported that mesenchymal
stem cells (MSCs) (obtained from the femora and tibiae of Dark Agouti rats) seeded onto
tripolyphosphate cross-linked chitosan microparticles resulted in a significant increase in
bone formation after 8 weeks of implantation in a partial thickness rat femur bone defect
as compared to a stainless steel plate control.85 Stephan et al. showed that an injectable
form of tissue engineered bone using a chitosan gel, MSCs and BMP-2 enhanced bone
formation in a rat calvarial critical sized defect.47 These studies with chitosan based bone
grafts are promising; however, the need for strength of bone graft substitutes has not been
met.
To take advantage of the many desirable characteristics of CTS and to enhance
mechanical properties, our research group developed a composite chitosan/nanohydroxyapatite microsphere-based scaffold.15,16 The microsphere-based scaffolds had
compressive strengths on par with lower range of cancellous bone (~10 MPa), supported
bone cell growth and mineralization in vitro, demonstrated biocompatibility and
osteoconductivity in a rat calvarial defect model, and when loaded with BMP-2 was
osteoinductive in a rat muscle pouch model.15,16,86 However, only 2% weight loss of
scaffolds was observed in vitro which may have limited the amount of new bone formed
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in vivo.15,16 Improvements in the degradation profile of the CTS microsphere-based
scaffolds may result in improved bone regeneration.
Our research strategy was to use CTS in conjunction with the co-polymer
poly(lactide-co-glycolide) or PLGA. PLGA is a biocompatible polymer that degrades via
hydrolysis, releasing acidic degradation products.30-32 Since CTS is soluble at acidic pH,
the degradation of the PLGA particles may help to increase the degradation of the CTS
microspheres. The aim of this study was to develop a novel composite CTS-PLGA
microsphere based system and evaluate the effect of different weight percent of PLGA
within CTS microspheres (0 wt %, 25 wt % and 50 wt %) on degradation rate and
compatibility with cultured cells. In this study, a 50:50 PLGA is used since this
formulation is hydrolytically unstable and is reported to completely degrade within
approximately 1-2 months.74 Composite CTS-PLGA and plain CTS microspheres were
prepared by a precipitation method. Our primary hypothesis is that the incorporation of
50:50 PLGA into CTS microspheres increases the overall degradation of the CTS
microspheres. Our secondary hypothesis is that incorporating 50:50 PLGA into
microspheres will have no cytotoxic effect on compatibility of composite microspheres
with osteoblasts.

Materials and Methods

Preparation and Characterization of PLGA Particles
50:50 PLGA (D,L-Lactide—46 mole%; Glycolide—54 mole%; Molecular
weight—3.2 KDa; Inherent viscosity—0.08dL/g; Lakeshore Biomaterials, Alabama,
USA) particles were prepared by modifying an emulsion-diffusion-evaporation technique

23

described by Betram et al. and Ravikumar et al. Briefly, a 2% weight/volume (w/v)
solution of 50:50 PLGA in acetone (50mL) was dripped drop wise into a 1% w/v solution
of polyvinyl alcohol (PVA) under magnetic stirring at 1200 rpm. The solution was
ultrasonicated at 35% amplitude using the following sequence: 20 seconds ON, 20
seconds OFF, 20 seconds ON, 20 seconds OFF, 20 seconds ON, and then added to a 5%
w/v solution of PVA and stirred at 350 rpm overnight in a fume hood. The emulsion was
then centrifuged at 13,500xg for 20 minutes, washed with DI water three times, resuspended in DI water and freeze dried for 24 hours to obtain PLGA particles. The
PLGA particles were stored in centrifuge tubes at -40C until further use. The prepared
PLGA particles were characterized for their crystallinity using x-ray diffraction (XRD)
spectrometry and thermal degradation properties using differential scanning calorimetry
(DSC).

Preparation of Composite Chitosan-PLGA Microspheres
Composite microspheres were prepared from a CTS (CTS) solution containing
PLGA. A 4.375 wt% solution of CTS powder (Degree of deacetylation—61%,
Viscosity—124cP, Primex, Iceland) was prepared in 2.5 v/v% acetic acid solution and
allowed to dissolve for 48 hours and then filtered using a nylon mesh with a pore
diameter of 180μm (Gilson Company, Inc., Ohio, USA). PLGA particles suspended in
water were added to the filtered CTS solution in the following weight ratios of
CTS:PLGA, a) 100:0 (CP0), b) 75:25 (CP25), and c) 50:50 (CP50) (Table 1). To form
microspheres, the PLGA-CTS solutions were dripped using a 16G needle and a syringe
pump set at a flow rate of 10μL/min into a cold base solution (50 wt% DI water, 30 wt%
methanol, and 20 wt% sodium hydroxide) to precipitate microspheres. The microspheres
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were allowed to sit in the base solution for 5 mins before being collected. Each batch of
collected microspheres was then washed thoroughly with DI water to neutral pH and
tested using a pH paper. The CTS-PLGA microspheres were air dried in a fume hood
overnight.

Amount of PLGA within Composite Chitosan-PLGA Microspheres
The amount of PLGA within each CTS-PLGA formulation was estimated by first
dissolving a given weight of each composite microsphere formulation in 2% v/v HAc
(aqueous phase) at a concentration of 10mg/mL for 2 hours. To this an equal volume of
dichloromethane (organic phase) was added, the solutions vortexed, and then allowed to
sit for 30 mins for the two layers to separate. The aqueous and organic phases were
collected separately and the samples were dried in a 500C oven for 24 hours. The amount
of CTS and PLGA within each composite microsphere was determined using the
equations below:

where, W is the weight of the composite CTS-PLGA microspheres, and W0 and WA are
the weight of the dried organic and aqueous phases of the composite CTS-PLGA
microspheres respectively.

Physicochemical Characterization Composite CTS-PLGA Microspheres
The physicochemical characterization of composite CTS-PLGA microspheres
was evaluated using confocal imaging to determine whether PLGA was incorporated in
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the composite microspheres; digital microscopy for surface topographical analysis; XRD
spectrometry to evaluate changes in crystallinity; and DSC to evaluate thermal
degradation properties.
For confocal imaging analysis, a fluorescent dye, Rhodamine-B (courtesy of Dr.
T. Fujiwara), was encapsulated within the PLGA particles using a double emulsiondiffusion-evaporation technique, prior to incorporating the PLGA particles within the
CTS microspheres. Samples were placed in a glass bottom Petri dish and observed with
the 10x objective of a Nikon A1 confocal laser fluorescence inverted microscope using
the 488 nm and 561 nm laser lines and the NIS-element imaging software. Surface
topographical analysis of the composite CTS-PLGA microspheres was performed using a
KEYENCE VHX 1000 digital microscope. Samples were placed on a glass slide and
viewed with a 100x objective eyepiece. In both cases, images of the composite CTSPLGA microspheres (CP25 and CP50) were compared to images of plain CTS
microspheres (CP0).
XRD analysis on the composite CTS-PLGA microspheres was performed on a
Bruker D8 Advance (Bruker AXS Inc., Madison, WI) using Cu-Kα radiation at 40 kV and
40mA. The diffraction patterns were obtained in the 2θ scan range of 4-400 with a step
size of 0.050 and a time/step of 0.2 s. DSC analysis of composite CTS-PLGA
microspheres was performed on a NETZSCH DSC 200 PC (NETZSCH DSC
Instruments, Germany). Samples were scanned from 250C to 4000C at 100C/min. The
XRD and DSC scans (n=3) for each of composite CTS-PLGA microspheres (CP25 and
CP50) were compared to the scans of plain CTS microspheres (CP0) and PLGA particles.
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In Vitro Degradation of Composite CTS-PLGA Microspheres
The in vitro degradation of composite CTS-PLGA microspheres was evaluated
over a 4 week period: Days 1, 3, 5, 7, 14, 21 and 28. A degradation solution of
100μg/mL concentration of lysozyme in 1x PBS with 1x AB/AM (Penicillin-10,000
IU/mL, Streptomycin-10mg/mL, Amphotericin B-25µg/mL) was used. Each treatment
group was gamma sterilized prior to starting the study.
Samples (n=4) for each of the composite CTS-PLGA treatment group was
weighed and placed in glass scintillation vials. To each sample, 2mL of degradation
solution was added and the samples were placed in an incubator at 370C with constant
shaking using a plate rocker. Every 72 hours, for 4 weeks, degradation solutions were
replenished. At each time point, the samples were washed with DI water three times
before drying in an oven at 400C for 24 hours, weighed and the percent change in mass
was determined from the before and after weights of the samples. The data were reported
as percent weight loss ± standard deviation.
In vitro degradation of the composite CTS-PLGA microspheres was also
evaluated using KEYENCE VHX 1000 digital microscope to analyze changes in surface
topography with degradation. The images of the composite CTS-PLGA microspheres at
each degradation time point (CP25 and CP50) were compared to the corresponding plain
CTS microspheres (CP0) for changes in size and surface topography of the microspheres.
Plain CTS microspheres (CP0) were used as a control for these studies.

In Vitro Cytocompatibility of Composite CTS-PLGA Microspheres
The cytocompatibility of the composite CTS-PLGA microspheres was evaluated
using a human osteosarcoma cell line (Saos-2, ATCC® Number: HTB-85™). The cell
27

attachment and growth study using Saos-2 cells was conducted in complete growth
medium composed of McCoy’s 5A Medium + 15% FBS + 1x AB/AM. Each treatment
group was gamma sterilized prior to starting the study.
Briefly, 100 microspheres of each composite CTS-PLGA treatment group were
placed in glass culture tubes, 13x100mm with screw cap (PYREX® Laboratory
Glassware, CORNING, MA, USA). 5mL of complete growth medium with cell
concentration of 106 cells/mL was added to each sample and gently agitated every 15
mins for four hours to ensure that the microspheres were evenly coated. After four hours,
the supernatant from each sample was gently decanted and the number of cells was
counted using a Z2 Coulter® Particle Count and Size Analyzer (Beckman Coulter, Inc.,
USA) to determine the percentage of cells attached to the surface of each of the
composite CTS-PLGA microspheres. The data were reported as percent cell attachment ±
standard deviation.
To each of the samples, 2mL complete growth medium was added and
replenished every 48 hours. Samples were evaluated at days 1, 3, 5 and 7 using the
CellTiter-Glo® Luminescent Cell Viability Assay (Promega, Wisconsin, USA) to
determine the growth of cells on the composite CTS-PLGA microspheres based on
quantification of the ATP present via the luciferase-luciferin reaction. The data were
reported as cell number/microsphere ± standard deviation.
Additionally, at each time point, the samples were evaluated using a
LIVE⁄DEAD® Viability⁄Cytotoxicity Kit for mammalian cells (Invitrogen Corporation,
California, USA) to determine the viability of cells on the composite CTS-PLGA
microspheres based on plasma membrane integrity and esterase activity of the cells.

28

Plain CTS microspheres (CP0) were used as a control for these studies.

Statistical Analysis
A two-factor ANOVA with Holm-Sidak post-hoc analysis was used to determine
any statistical difference between treatment groups. A p value of < 0.05 was deemed
significant.

Results

Physiochemical Characterization
After the formulation of the composite CTS-PLGA microspheres via the
precipitation method, the actual amount of PLGA within the microspheres was estimated.
It was found that CP25 actually had 7.5wt% PLGA, while CP50 had 12.7wt% PLGA
(Table 1).

Table 1. Composite CTS-PLGA formulations and actual CTS and PLGA weight
percentage in the composite microspheres
Composite
Theoretical Theoretical
Actual
Actual
*
CTS-PLGA formulation CTS wt% PLGA wt% CTS wt % PLGA wt %*

*

CP0

100

0

100

0

CP25

75

25

92.5

7.5

CP50

50

50

87.4

12.6

n=1

Confocal image analysis using a Nikon A1 confocal laser microscope system was
used to validate whether PLGA was incorporated within the composite CTS-PLGA
microspheres. Using a 3D stack feature, it appeared that the plain CTS microspheres did
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not fluoresce in the TRITC range due to the lack of Rhodamine-B encapsulated PLGA
particles; however, CP0 auto-fluoresced slightly (Image not shown). For CP50, that had
PLGA particles encapsulated with Rhodamine-B, the microspheres fluoresced red in the
TRITC range and all of the fluorescence in CP50 was observed to be well distributed on
the surface of these composite microspheres (Figure 1A, B and C). Furthermore, certain
areas of the composite CTS-PLGA microspheres were not covered by PLGA particles,
but instead had holes on the surface as indicated in Figure 1C.
The surface topographical analysis of composite CTS-PLGA microspheres was
evaluated using a digital microscope. A Quick Depth Composition and 3D feature was
used on the KEYENCE VHX 1000 digital microscope to get 3D stack images of the
composite CTS-PLGA microspheres (Figure 2). Examination of the surface topography
of the microspheres reveals that as the PLGA content in the CTS microsphere increases,
there is an increase in a white appearance of the composite CTS-PLGA microspheres as
compared to CP0.
The crystallinity of composite CTS-PLGA microspheres was studied using XRD.
Representative XRD spectra of the composite CTS-PLGA microspheres, plain CTS
microspheres and PLGA particles are shown in Figure 3. CP0 exhibited a large hydrous
crystalline peak at around 2θ=120 and a very small anhydrous peak at 2θ=200. With the
addition of varying amounts of PLGA to the CTS microspheres, the hydrous crystalline
peak at around 2θ=120 reduced in intensity while the anhydrous peak at 2θ=200
disappeared. Hence, both CP25 and CP50 have reduced peaks at 2θ=100 and no
crystalline peaks at 2θ=200. Due to the absence of a crystalline peak at 2θ=200, the
crystallinity indices of composite CTS-PLGA microspheres and plain CTS microspheres
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could not be calculated. A small peak, similar to that of CP25, was noticed at around
2θ=120 for PLGA particles.

C

A

Hole

B

Figure 1. Confocal images of composite CTS-PLGA microspheres. Images were taken
in the TRITC region with a Nikon A1 confocal laser microscopy using a 10x objective
and a 3D stack feature. A: Section of CP50 seen from a default x, y, z view; B: Section
of CP50 seen from + x-axis; C: Section of CP50 seen from + z-axis. CP50 fluoresced red
due to the presence of PLGA within the composite microsphere; all the PLGA particles
were well distributed on the surface of the microsphere giving it a rough and textured
surface. Arrow indicates area on the surface of CP50 where holes were observed.

Table 2. Exothermic and endothermic peak temperatures of composite Chitosan-PLGA
microspheres
Composite
Endothermic
Exothermic
0
CTS-PLGA formulation peak temp ( C) peak temp (0C)
CP0

102.3 ± 7.9

300 ± 0.2*

CP25

99.9 ± 3.7

298.9 ± 0.3

CP50

92.8 ± 0.6

299.2 ± 0.0

* Statistically different (p < 0.05)
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CP0

CP25

CP50

Figure 2. Surface topographical analysis of composite CTS-PLGA microspheres
compared to plain CTS microspheres. Images were taken using Quick Depth
Composition and 3D feature on the KEYENCE VHX-1000 digital microscope using a
100x objective. CP0: Plain CTS microspheres; CP25: CTS microspheres with 25wt%
PLGA; CP50: CTS microspheres with 50wt% PLGA. The composite CTS-PLGA
microspheres (CP25 and CP50) have a visually white surface compared to the plain CTS
microspheres (CP0).
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The thermal degradation of composite CTS-PLGA microspheres was analyzed
using DSC. Representative DSC thermograms and a summary of endothermic and
exothermic peak temperatures of composite CTS-PLGA microspheres can be found in
Figure 4 and Table 2 respectively. DSC analyses revealed that CP0 had a higher
endothermic peak as compared to CP25 and CP50, however, no differences were seen
between treatment groups (p = 0.25). ANOVA analysis showed that there were
differences in the exothermic peaks between treatment groups (p = 0.0015). Post-hoc
analysis revealed that CP0 was different and significantly higher than CP25 and CP50,
and there were no differences in the exothermic peak temperatures of CP25 and CP50.

PLGA

CP0

Relative Intensity

2500

CP25

CP50

Peak @ 2θ =120

2000

Peak @ 2θ =200
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1000
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0
0
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40

45

2θ (in degrees)
Figure 3. Representative XRD spectra of composite CTS-PLGA microspheres compared
with plain CTS microspheres and PLGA particles. CP0: Plain CTS microspheres; CP25:
CTS microspheres with 25wt% PLGA; CP50: CTS microspheres with 50wt% PLGA. A
shift in the hydrous peak at 2θ=100 to 2θ=120 is noticed for CP0 with a tiny anhydrous
peak at 2θ=200. A decrease in peak size is seen at around 2θ=120 and 2θ=200 with the
increase in PLGA content within the composite microspheres.
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Figure 4. A. Representative DSC thermograms of composite CTS-PLGA microspheres
compared with plain CTS microspheres and PLGA particles over the entire temperature
range (250 – 4000C). B. Glass transition temperature regions of PLGA particles
compared with composite CTS-PLGA microspheres. CP0: Plain CTS microspheres;
CP25: CTS microspheres with 25wt% PLGA; CP50: CTS microspheres with 50wt%
PLGA. A slight reduction in exothermic peak temperatures is seen with the incorporation
of PLGA within the CTS microspheres.
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Degradation Study
The degradation of composite CTS-PLGA microspheres was evaluated over 4
weeks in a 100μg/mL solution of lysozyme in 1x PBS with 1x AB/AM. Loss in weight
of the composite microspheres at each time point was used as a measure of percent
weight change over time. Results of two-way ANOVA analysis revealed that there was a
difference in percent weight change between composite CTS-PLGA treatment groups (p
< 0.001) as well as a difference between days (p < 0.001) and there was a significant
interaction between CTS-PLGA treatment groups and day factor (p < 0.001). Significant
interaction indicates that the degradation of the composite CTS-PLGA microspheres
depended upon the composite formulation as well as time spent in the degradation
solution. The results of the degradation study are summarized in Figure 5.
Post-hoc analysis of each composite CTS-PLGA microsphere treatment group
showed that there was a significant increase in weight loss over the 28 day period with
the maximum loss seen on day 28. Furthermore, post-hoc analysis between composite
CTS-PLGA microspheres on a daily basis showed that there was no difference between
treatment groups on days 1, 3 and 5. However, differences were seen on days 7, 14, 21
and 28, with CP50 and CP0, in general, having the highest and lowest percent weight
changes respectively. On day 28, CP50 was significantly different from CP25 and CP0,
but no differences were seen between CP25 and CP0. To summarize, at day 28, CP50
had the largest weight loss of 28.9% ± 1.4%, while CP0 had the lowest weight loss of
25.2% ± 0.3%.
At each time point in the degradation study, images of the composite CTS-PLGA
microspheres were taken using a digital microscope to evaluate changes in surface
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topography of the microspheres with degradation time (Figure 6). It was observed that
within each treatment group the microspheres reduce in size with degradation time.
Furthermore, the white appearance of the composite CTS-PLGA microspheres becomes
less evident with degradation time, becoming more similar to that of plain CTS
microspheres (Figure 6).
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Figure 5. Degradation of composite CTS-PLGA microspheres over a 28 day period
carried out in a 100μg/mL solution of lysozyme in 1x PBS with 1x AB/AM (n=4). The
results are represented as percent weight change ± standard deviation on a linear scale.
CP0: Plain CTS microspheres; CP25: CTS microspheres with 25wt% PLGA; CP50: CTS
microspheres with 50wt% PLGA. A significant difference in the percent weight change
was observed between composite CTS-PLGA treatment groups as well as a significant
difference between days was observed. At day 28, CP50 had the largest weight loss
while CP0 had the lowest weight loss. (* difference between groups, p < 0.01; §
differences vs. all other groups, p < 0.005; † differences against all previous time points,
p < 0.005)
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Figure 6. Digital images of composite CTS-PLGA microspheres over a 28 day
degradation period carried out in 100μg/mL solution of lysozyme in 1x PBS with 1x
AB/AM. CP0: Plain CTS microspheres; CP25: CTS microspheres with 25wt% PLGA;
CP50: CTS microspheres with 50wt% PLGA. The overall size and white appearance of
the composite CTS-PLGA microspheres reduce with degradation time when compared to
plain CTS microspheres. Scale shown: 500μm
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Cell Attachment and Proliferation Study
Cellular attachment and proliferation on the composite CTS-PLGA microspheres
was studied using a human osteosarcoma cell line, Saos-2. For cellular attachment, oneway ANOVA analysis revealed that there was a difference in cellular attachment between
the different composite CTS-PLGA microspheres (p = 0.043). Post-hoc analysis showed
that there was a significant difference in the percent cell attachment between CP25 and
CP0 (p = 0.017); CP25 had the highest percent cell attachment of 35.3% ± 5.5%, while
CP0 had the lowest percent cell attachment of 23.1% ± 7.7% (Figure 7).
For proliferation, the results of the two-way ANOVA analysis revealed that there
was a difference in cellular growth between composite CTS-PLGA treatment groups (p =
0.006) as well as a difference over time (p < 0.001) and there was a significant interaction
between CTS-PLGA treatment groups and day factor (p = 0.016). Significant interaction
indicates that cellular proliferation on the composite CTS-PLGA microspheres depended
upon composite formulation and time. The results of the proliferation study are
summarized in Figure 8.
Overall, cells increased in number on all treatment groups over the 7 day cell
culture period. At earlier time points, the number of cells/microsphere was higher for
composite CTS-PLGA treatment groups. However, by day 7, there were no differences
between the treatment groups. Post-hoc analysis indicated that there was no significant
difference in number of cells/microsphere between composite CTS-PLGA microsphere
groups over the 7 day test period. On day 1, significant differences in number of
cells/microsphere were observed between CP0 and composite CTS-PLGA microsphere
treatment groups. For each composite CTS-PLGA microsphere treatment group, post-
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hoc analysis showed that there were no significant differences in number of
cells/microsphere between days for CP25. For CP0, the number of cells/microsphere on
day 7 was significantly greater than days 1, 3 and 5. For CP50, significant increase in the
number of cells/microsphere was seen between days 3 and 5.
LIVE/DEAD images of the composite microspheres were taken to assess the
viability of Saos-2 cells on these microsphere treatment groups at each time point in the
proliferation study. Images were taken using a Nikon ECLIPSE TE300 microscope with
BIOQUANT OSTEO II software (Figure 9). Qualitatively, it was observed that the
number of cells/microsphere increases for all treatment groups between days 1 and 3.
The number of cells/microsphere between days 3, 5 and 7 look similar within each
treatment group. Furthermore, no differences in the number of cells/microsphere were
seen between treatment groups on each of the days.
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Figure 7. Percent cell attachment of human osteosarcoma epithelial cell line, Saos-2,
after 4 hours on composite CTS-PLGA microspheres (n=4). The results are represented
as percent cell attachment ± standard deviation. CP0: Plain CTS microspheres; CP25:
CTS microspheres with 25wt% PLGA; CP50: CTS microspheres with 50wt% PLGA.
CP25 exhibited the highest percent cell attachment, while CP0 exhibited the least percent
cell attachment. * difference between groups (p = 0.017)
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Figure 8. Proliferation of human osteosarcoma epithelial cell line, Saos-2, on composite
CTS-PLGA microspheres over a 7 day period using the CellTiter-Glo® Luminescent
Cell Viability Assay (n=4). The results are represented as number of cell/microsphere ±
standard deviation. CP0: Plain CTS microspheres; CP25: CTS microspheres with 25wt%
PLGA; CP50: CTS microspheres with 50wt% PLGA. Cells increased in number on all
treatment groups over the 7 day cell culture period. The number of cells/microsphere
was higher for composite CTS-PLGA treatment groups at earlier time points, however,
by day 7, there were no differences seen. (§ differences vs. all other groups, p < 0.05; †
differences against all previous time points, p < 0.005)
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Figure 9. Proliferation of human osteosarcoma epithelial cell line, Saos-2, on composite
CTS-PLGA microspheres over a 7 day period evaluated using LIVE/DEAD®
Viability⁄Cytotoxicity Kit for mammalian cells. CP0: Plain CTS microspheres; CP25:
CTS microspheres with 25wt% PLGA; CP50: CTS microspheres with 50wt% PLGA.
The number of cells/microspheres increases between day 1 and 3 for all treatment groups,
but remains constant thereafter. At each time point, no differences in number of
cells/microsphere were observed between treatment groups.
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Discussion
A composite chitosan-poly(lactide-co-glycolide) microsphere based system was
designed and evaluated for bone tissue engineering applications. The rationale for this
design was that acidic degradation by-products of PLGA particles would help to facilitate
the degradation of CTS microspheres with the ultimate goal of improving the overall
degradation of composite CTS-PLGA microspheres for bone tissue regeneration. Our
primary hypothesis was that the addition of 50:50 PLGA particles to the CTS
microspheres would increase the overall degradation of the composite microspheres as
compared to plain CTS microspheres. Our secondary hypothesis was that the addition of
50:50 PLGA to the CTS microspheres would have no cytotxic effect on compatibility of
composite microspheres with osteoblasts. The effects of varying ratios of PLGA
particles incorporated into CTS microspheres was examined based on morphology,
crystallinity, thermal degradation properties, in vitro degradation and in vitro cell
attachment and proliferation of osteoblasts on composite microspheres as compared to
plain CTS microspheres.
We found that the PLGA amount within the various composite CTS-PLGA
microsphere formulations were lower than the prescribed formulations—only 7.5 wt%
and 12.6wt% PLGA were incorporated in the CP25 and CP50 formulations respectively
instead of the theoretical 25wt% and 50wt%. A 3D stack confocal image of CP50
revealed that PLGA particles were well distributed on the surface of these microspheres
and certain areas on the surface had visible holes/voids with no visible PLGA particles.
These results indicate poor incorporation of PLGA particles within the composite
microspheres. The reasons for poor incorporation of PLGA within the composite
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microspheres may be attributed to a few reasons; 1) degradation of PLGA while in
chitosan-acetic acid solution prior to precipitation, 2) degradation of PLGA within the
microspheres prior to neutralization, and 3) degradation and/or loss of PLGA particles
during washing steps. In particular, while preparing Rhodamine-B encapsulated PLGACTS microspheres for confocal image analysis, it was observed that the precipitating and
washing solutions rapidly turned pink indicating loss of Rhodamine-B encapsulated
PLGA particles during these steps. Alternative mixing methods, such as using a dualsyringe system that would mix chitosan in acetic acid solution and PLGA particle
suspension in water to form microspheres just prior to dripping; and/or other precipitating
solvents, such as a 0.5M sodium sulfate, 1M sodium hydroxide, and distilled water (3:1:6
v/v) may be investigated.81 Alternatively, other PLGA formulations, such as 85:15
PLGA, that are not as susceptible to degradation in aqueous solutions may be used and
investigated. However, these formulations have slower degradation rates and hence their
effects on driving the degradation of CTS microspheres may be less pronounced than
50:50 PLGA.
Digital microscopy of the microspheres revealed that there was a difference in the
overall morphology of the composite CTS-PLGA microspheres as compared to plain
CTS microspheres. Composite microspheres appeared whiter as compared to plain CTS
microspheres which are a result of the addition of varying contents of PLGA to the CTS
microspheres. Confocal imaging revealed that the surfaces of composite CTS-PLGA
microspheres looked rough and textured due to the PLGA particles. Jiang et al. have
reported that CTS-PLGA microspheres have a visually rougher surface as compared to
PLGA microspheres that have a smoother surface.83 Findings from confocal imaging
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show that a majority of the PLGA particles in our composite microspheres is on the
surface of these microspheres. The mechanism for why PLGA preferentially segregates
to the surface is unclear. It may be due in part because during the preparation of
composite microspheres the PLGA particles were hydrolyzed either during the mixing,
precipitation and/or washing processes and hence only residual PLGA material was
retained on the surface of the composite microsphere.
CTS generally exhibits two prominent crystalline peaks at 2θ=100 and 2θ=200.87
However, an absence in crystalline peaks at 2θ=200 was noticed for all treatment groups.
A similar result was reported by Mecwan et al., wherein CTS sponges prepared by
lyophilization also did not exhibit any crystalline peak at 2θ=200.88 However, Chesnutt et
al. reported seeing crystalline peaks at 2θ=200 in CTS microspheres that were prepared
via a similar precipitation method where the microspheres were allowed to precipitate
and remain in the base solution for 24 hours.15 The reason for the loss of the anhydrous
crystalline peak at 2θ=200 in all the treatment groups may be ascribed to the method used
to prepare these microspheres as well as differences in DDA of CTS materials used.
Since the microspheres were only allowed to precipitate and remain in the base solution
for 5 mins before they were removed and washed, this would not be enough time for the
crystalline phases within the microspheres to form. Additionally, it must be noted that
for this study we used a 61% DDA CTS polymer as compared to a 92.3%DDA CTS
polymer that was used by Chesnutt et al.15 It is well known that CTS polymers with
higher DDA have higher crystallinity.89,90 This is because CTS polymer chains with a
higher DDA have smaller amino side groups and can pack more efficiently as compared
to CTS polymer chains with lower DDA which have larger acetyl side groups and cannot
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pack as efficiently resulting in reduced crystallinity. Hence, the reduced crystallinity
seen in all treatment groups is a result of using a CTS polymer with lower DDA.
Furthermore, as the PLGA content in the composite microspheres was increased,
a reduction in the hydrous crystalline peak at 2θ=120 was noticed. 50:50 PLGA is an
amorphous polymer, hence, it would be expected that the increased amount of PLGA in
the composite CTS-PLGA microspheres would result in the disruption of the crystalline
chains within CTS polymer, causing the composite CTS-PLGA microspheres to be more
amorphous as compared to plain CTS microspheres. These results are similar to MartelEstrada et al., wherein they saw a reduction in crystallinity of their chitosan sponges with
the addition of PLGA.91 Interestingly, it was also observed that the composite CTS-PLGA
microspheres had exothermic peak temperatures that were significantly smaller than that of
plain CTS microspheres. However, it must also be noted that the reduction in the

exothermic peak temperatures seen due to the addition of PLGA to the CTS microspheres
is very small and may not be practically important. Furthermore, most chitosan materials
with different DDA and molecular weights show exothermic peak temperatures in the
3000C range.92
In vitro degradation studies on composite CTS-PLGA microspheres were
conducted to evaluate the effect of varying PLGA content in the composite microspheres
on the degradation of composite microspheres. CP0 had ~15wt% loss after a 14 day
degradation period as compared to ~2wt% loss reported by Chesnutt et al. for the same
degradation time.15 This discrepancy in the degradation of plain chitosan microspheres
can be attributed to the reduced crystallinity of CP0 which would have resulted in higher
degradation due to loser chain packing of the CTS polymer making the polymer chains
more susceptible to enzymatic degradation by lysozyme as compared to the highly
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crystalline chitosan microspheres (crystallinity index of ~80%) prepared by Chesnutt et
al.15 It was hypothesized that the addition of 50:50 PLGA particles to the CTS
microspheres would increase their overall degradation rate as the acidic degradation byproducts of PLGA would help CTS microspheres to degrade faster. Jiang et al. reported
that the addition of CTS to PLGA microspheres reduced the degradation rate of their
composite CTS-PLGA sintered microspheres to ~0.5wt% loss as compared to 1.5wt%
loss seen for PLGA sintered scaffolds after 12 weeks of degradation.84 Hence, the results
of our degradation study correlates with that of Jiang and coworkers—as the weight
percent of CTS in the composite microspheres increase their degradation rates are lower
as compared to composite microspheres with higher weight percent of PLGA.
Furthermore, from the digital images of the composite CTS-PLGA microspheres
taken during the degradation study it can be seen that the microsphere size of all
treatment groups reduce over time which would suggest overall degradation of the
microspheres. Moreover, the whiter appearance of the composite CTS-PLGA
microspheres also reduces over time, and by day 28, all treatment groups look similar to
each other. This difference in appearance of the composite CTS-PLGA microspheres, as
previously stated, is attributed to the addition of PLGA to the CTS microspheres. Hence,
a reduction in the whiter appearance of composite microspheres over time would suggest
that the PLGA portion of the composite microspheres is degrading at a rate faster than the
CTS portion of the microspheres. This result is not surprising as we used 50:50 PLGA in
our composite microspheres which is known to degrade within 1-2 months.74 At this
point, however, it is uncertain whether any loss in mass seen in the composite
microspheres was solely due to PLGA particles or a combinatory effect of PLGA
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particles and a lower crystalline CTS polymer. Furthermore, the mechanism by which
PLGA aids in the degradation of CTS is presently unknown and further studies would
need to be conducted to understand this mechanism. This would be important so that the
degradation rate of the CTS microspheres can be optimized and tailored for specific bone
tissue engineering applications by the addition of varying amounts of PLGA.
In vitro cell viability studies on composite CTS-PLGA microspheres were
conducted to observe if there were any cytotoxic effects associated with the varying
amounts of PLGA within the composite microspheres due to its acidic degradation
products. CP0 had a cell attachment of ~23% Saos-2 cell attachment as compared to the
observed 42% and 55% HEPM cell attachments reported by Reves et al. and Chesnutt et
al. respectively for composite chitosan-hydroxyapatite microsphere scaffolds.15,17 This
reduced attachment seen for CP0 and the other treatment groups can be a result of a
higher seeding density used for this study (5 x 106 cells/sample) as compared to the 105
cells/sample seeding concentrations used by Reves et al and Chesnutt et al.15,17
Additionally, some cells may have attached to the glass culture tubes which were not
accounted for; as a result, we may have underestimated the percent cell attachment.
Furthermore, it is widely known that surface topography and roughness of materials plays
an important role in cellular attachment and proliferation.93,94 From the in vitro cell
attachment studies it was observed that the presence of PLGA within the composite CTSPLGA microspheres significantly impacted the attachment of Saos-2 cells on the
microspheres. As noted earlier, the composite CTS-PLGA microspheres exhibited a
more roughened texture than plain CTS microspheres which may have resulted in a
greater percent cell attachment for the composite CTS-PLGA microspheres.
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Furthermore, it was also observed that CP25 showed a greater, but not significant,
percent cell attachment than CP50. It is known that PLGA is a hydrophobic polymer and
hence, increasing the PLGA content of the composite microspheres would increase the
overall hydrophobicity of the surface of the composite microsphere and prevent cell
attachment proteins to bind to such surfaces.95,96 Hence, the differences in the attachment
of Saos-2 cells to the composite CTS-PLGA can be attributed to a combination of the
differences in the surface topography and hydrophobicity of the composite CTS-PLGA
microspheres.
Moreover, the in vitro proliferation study as well as LIVE/DEAD images of the
microspheres revealed that there were no differences in number of cells/microsphere
between the treatment groups over the 7 day period. However, it should be noted that the
cells on CP0 grew at a faster rate, but not significantly, when compared to composite
CTS-PLGA microspheres. It is well known that PLGA materials produce acidic
degradation by-products which inhibit cellular growth. This may be the case with our
composite CTS-PLGA microspheres too, but the added benefit of a more favorable
surface for the cells to attach and proliferate on the composite CTS-PLGA microspheres
could potentially counteract the deleterious effects the acidic degradative by-products of
PLGA may have on osteoblastic cellular growth. Overall, these findings are in
accordance with the results by Nandagiri et al., who reported that the addition of PLGA
nanoparticles to chitosan-gelatin scaffolds did not significantly affect cell attachment and
viability of clonal human osteoblast cell line, hFOB, over an 11 day cell culture period.82
Hence, we can support our hypothesis that incorporating 50:50 PLGA into CTS
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microspheres will have no cytotoxic effect on compatibility of composite CTS-PLGA
microspheres with osteoblasts.
The results of this study show that even though all PLGA particles did not get
incorporated into the composite CTS-PLGA microspheres, there are PLGA particles on
the surface. This layer of PLGA particles on the surface could act as a barrier to slow
down release of drugs that are encapsulated within the CTS microsphere, and to test the
potential of these composite CTS-PLGA microspheres as potential drug delivery
vehicles, future studies will be aimed at loading the PLGA particles and CTS
microspheres with drugs and assessing the dual drug release kinetics from these
composite microspheres. Furthermore, it would be of interest, primarily from a tissue
engineering and drug delivery point of view, to fabricate these composite CTS-PLGA
microspheres into 3D bone constructs and assess these constructs to regenerate bone in an
in vivo model.

Conclusions
A new composite CTS-PLGA microsphere based system was successfully
fabricated via a precipitation method. The precipitation method used to prepare the
composite CTS-PLGA microspheres resulted in only a small amount of PLGA being
incorporated into the composite microspheres as compared to the theoretical formulations
of the composite microspheres. Moreover, the PLGA within the composite microspheres,
being hydrophobic, preferentially segregated to the surface of the microsphere, resulting
in a roughened texture of the composite CTS-PLGA microspheres. Furthermore, the
addition of PLGA to the CTS microspheres resulted in a reduced crystallinity which can
be reflected in the reduced exothermic peak temperatures; had higher weight loss at the
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end of 28 days as well as exhibited better cellular attachment. However, there were no
differences seen in the proliferation of osteoblasts between the plain CTS microspheres
and composite CTS-PLGA microspheres at the end of the 7 day cell culture period.
Overall, even though only a small portion of PLGA was incorporated into the composite
microsphere, they had higher degradation and better cell attachment properties compared
to plain CTS microspheres, showing that these composite CTS-PLGA microspheres have
a good potential as bone graft substitutes in bone tissue engineering applications.
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CHAPTER 4: CONCLUSIONS
In this preliminary in vitro study, novel composite CTS-PLGA microspheres for
bone tissue engineering applications were successfully fabricated using a precipitation
method. The potential of these composite CTS-PLGA microspheres in bone tissue
engineering applications was assessed by evaluating the physiochemical, degradative and
biological effects of incorporating varying amounts of PLGA particles into CTS
microspheres.
It was found that the precipitation method used to prepare the composite CTSPLGA microspheres resulted in only a small amount of PLGA being incorporated into
the composite microspheres as compared to the theoretical formulations of the composite
microspheres. Moreover, the PLGA within the composite microspheres, being
hydrophobic, preferentially segregated to the surface of the microsphere as compared to
the aqueous core of the microspheres. This resulted in a roughened texture of the
composite CTS-PLGA microspheres as compared to plain CTS microspheres.
Furthermore, the addition of PLGA to the CTS microspheres resulted in a reduced
crystallinity of the composite microspheres which can be reflected in the reduced
exothermic peak temperatures of the composite CTS-PLGA microspheres as compared to
the plain CTS microspheres.
Overall, even though the incorporation of PLGA was low within the composite
CTS-PLGA microspheres, they had a higher weight loss or degradation at the end of 28
days as well as better cellular attachment as compared to plain CTS microspheres.
However, there were no differences seen in the proliferation of osteoblasts between the
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plain CTS microspheres and composite CTS-PLGA microspheres at the end of the 7 day
cell culture period.
Hence, the results of our study show that we can support our hypotheses that the
incorporation of PLGA into CTS microspheres increased the overall degradation rate of
the microspheres; and the composite CTS-PLGA microspheres were compatible with
osteoblasts and had no evident deleterious effects due to the acidic degradation byproducts of PLGA.
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CHAPTER 5: FUTURE WORK
The results of this study showed that only a small amount of PLGA was actually
incorporated into the microspheres as compared to the theoretical formulations of the
composite microspheres. This reduced amount was attributed to the extremely alkaline
base solution that was used to precipitate the composite microspheres which may have
resulted in preliminary degradation of the PLGA particles. Hence, future studies will aim
at exploring alternative base solutions and methods for the precipitation of these
composite microspheres as well as methods for a more uniform distribution of PLGA
particles within the microspheres; to allow for maximum incorporation of PLGA within
the composite microspheres. This will result in maximum loading and minimal loss of a
drug of interest within PLGA particles and will be particularly important from a drug
delivery perspective.
Furthermore, the results of this study suggest that the composite CTS-PLGA
microsphere based system may have the potential to be used as a dual drug delivery
vehicle for bone tissue engineering applications. A possible suggestion is to encapsulate
a hydrophobic drug within the PLGA particles while hydrophilic drugs can be
encapsulated within the CTS microsphere. The PLGA particles that segregated to the
surface of the composite microsphere would provide a means for rapid delivery of the
hydrophobic drug, whereas, the hydrophilic drug encapsulated within the CTS
microspheres would have an extended release as the PLGA particles on the surface of the
microsphere would act as a barrier, slowing down the release of the drug from the
microsphere. To test these composite CTS-PLGA microspheres as potential dual drug
delivery vehicles, future studies will be aimed at loading the PLGA particles and CTS
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microspheres with hydrophobic and hydrophilic drugs respectively, as mentioned above,
and assessing the dual drug release kinetics from these composite microspheres.
Moreover, different methods and techniques for fusing these composite CTSPLGA microspheres to fabricate them into 3D bone scaffold constructs and studying their
mechanical properties should be explored. Moreover, it would be of interest to conduct a
long-term degradation study on these composite CTS-PLGA bone scaffold constructs and
evaluate their mechanical integrity over the degradation time period. It may also be
important to evaluate the long term effects of cell growth pattern on the composite CTSPLGA bone scaffold constructs as well as the evaluation of other cellular parameters and
bone cell mineralization markers, such as alkaline phosphatase, calcium content, collagen
type I, collagen type II, osteopontin, osteocalcin and bone sialoprotein.

Finally, it would be of interest, primarily from a bone tissue engineering and drug
delivery point of view, to assess the ability of these composite CTS-PLGA 3D
microsphere based scaffolds to form new bone tissue, while simultaneously degrading and
releasing drugs in an animal model in vivo.
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APPENDIX A: PREPARATION OF CP5 COMPOSITE MICROSPHERES

CP5 composite microspheres or 5 wt% PLGA particles within chitosan
microspheres were prepared similarly to the other composite CTS-PLGA weight
formulations as previously described. Briefly, a 4.375 wt% solution of CTS powder
(Degree of deacetylation—61%, Viscosity—124cP, Primex, Iceland) was prepared in 2.5
v/v% acetic acid solution and allowed to dissolve for 48 hours and then filtered using a
nylon mesh with a pore diameter of 180μm (Gilson Company, Inc., Ohio, USA). PLGA
particles suspended in water were added to the filtered CTS solution so that the final
concentration of PLGA in the solution was 5wt%. To form microspheres, the PLGACTS solutions were dripped using a 16G needle and a syringe pump set at a flow rate of
10μL/min into a cold base solution (50 wt% DI water, 30 wt% methanol, and 20 wt%
sodium hydroxide) to precipitate microspheres. The microspheres were allowed to sit in
the base solution for 5 mins before being collected. Each batch of collected CP5
composite microspheres was then washed thoroughly with DI water to neutral pH and
tested using a pH paper. The CTS-PLGA microspheres were air dried in a fume hood
overnight.
Once prepared, physiochemical characterization, in vitro degradation studies and
in vitro cellular attachment and proliferation studies were performed on CP5 composite
microspheres as described in the subsequent appendices.
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APPENDIX B: PHYSIOCHEMICAL CHARACTERIZATION OF CP5
COMPOSITE MICROSPHERES
The physicochemical characterization of CP5 composite microspheres was
evaluated using XRD spectrometry to evaluate changes in crystallinity; and DSC to
evaluate thermal degradation properties.
As previously described, XRD analysis on CP5 microspheres was performed on a
Bruker D8 Advance (Bruker AXS Inc., Madison, WI) using Cu-Kα radiation at 40 kV and
40mA. The diffraction patterns were obtained in the 2θ scan range of 4-400 with a step
size of 0.050 and a time/step of 0.2 s. DSC analysis of composite CTS-PLGA
microspheres was performed on a NETZSCH DSC 200 PC (NETZSCH DSC
Instruments, Germany). Samples were scanned from 250C to 4000C at 100C/min. The
XRD and DSC scans (n=3) for CP5 composite microspheres were compared to the scans
of plain CTS microspheres (CP0) and PLGA particles.
The results of XRD analysis revealed that CP5 had crystalline peaks at 2θ = 120
and 2θ = 200 as compared to CP0 which had a large hydrous crystalline peak at 2θ = 120
but an almost absent anhydrous crystalline peak at 2θ = 200 (Figure 1). However, with
the increase in PLGA content it is noticed that the hydrous crystalline peak at 2θ = 120
reduces (Figure 1).
The results of DSC analysis revealed that there were no differences in the
endothermic peak temperatures between CP0 and CP5 (p = 0.963). However, CP5 had a
significantly lower exothermic temperature of 298.6 ± 0.10C as compared to CP0 with
exothermic temperatures of 300.0 ± 0.20C (p < 0.001). This reduction in exothermic
temperature may be attributed to the addition of PLGA. It must be noted that the
reduction in exothermic peak is extremely small and may not be of practical importance.
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Figure 1. Representative XRD spectra of CP5, CTS microspheres with 5wt% PLGA,
compared with plain CTS microspheres (CP0) and PLGA particles. A shift in the hydrous
peak at 2θ=100 to 2θ=120 is noticed for CP0 with a tiny anhydrous peak at 2θ=200. A
decrease in peak size is seen at around 2θ=120, but a crystalline anhydrous peak at 2θ=200
is seen for CP5.

Figure 2. Representative DSC spectra of CP5, CTS microspheres with 5wt% PLGA,
compared with plain CTS microspheres (CP0) and PLGA particles. A reduction in
exothermic peak temperatures is seen in CP5 due to the incorporation of PLGA within the
CTS microspheres.
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APPENDIX C: IN VITRO DEGRADATION OF CP5 COMPOSITE
MICROSPHERES
The in vitro degradation of CP5 composite microspheres was also evaluated over
a 4 week period: Days 1, 3, 5, 7, 14, 21 and 28. A degradation solution of 100μg/mL
concentration of lysozyme in 1x PBS with 1x AB/AM (Penicillin-10,000 IU/mL,
Streptomycin-10mg/mL, Amphotericin B-25µg/mL) was used. Each treatment group
was gamma sterilized prior to starting the study.
As previously described, CP5 samples (n=4) were weighed and placed in glass
scintillation vials. To each sample, 2mL of degradation solution was added and the
samples were placed in an incubator at 370C with constant shaking using a plate rocker.
Every 72 hours, for 4 weeks, degradation solutions were replenished. At each time point,
the samples were washed with DI water three times before drying in an oven at 400C for
24 hours, weighed and the percent change in mass was determined from the before and
after weights of the samples. The data were reported as percent weight loss ± standard
deviation. In vitro degradation of CP5 composite microspheres were also evaluated using
KEYENCE VHX 1000 digital microscope to analyze changes in surface topography with
degradation.
The results of the one-way ANOVA analysis showed that there was an increase in
weight percent loss of CP5 microspheres over the 28 day degradation period (p < 0.001).
Post-hoc analysis revealed that there were no differences between days 1, 3, 5 and 7.
However, differences were noticed between days 14, 21 and 28. Overall, at the end of the
28 day degradation period, CP5 had a weight percent loss of 26.2 % ± 0.9% (Figure 3).
Furthermore, digital images taken of CP5 microspheres show that the overall size as well
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as the white texture of the microspheres reduces over the 28 day degradation time period
(Figure 4).
†
†

†

Figure 3. Degradation of CP5, CTS microspheres with 5wt% PLGA, over a 28 day
period carried out in a 100μg/mL solution of lysozyme in 1x PBS with 1x AB/AM
(n=4). The results are represented as percent weight change ± standard deviation. At
day 28, CP5 had a weight loss of 26.2% ± 0.9%. († differences against all previous time
points, p < 0.001)

Day 0

Day 7

Day 14

Day 21

Day 28

Figure 4. Digital images of CP5, CTS microspheres with 5wt% PLGA, over a 28 day
degradation period carried out in 100μg/mL solution of lysozyme in 1x PBS with 1x
AB/AM. The overall size and white, glass-like texture of the composite CTS-PLGA
microspheres reduce with degradation time similar to the other composite CTS-PLGA
microspheres. Scale shown: 500μm
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APPENDIX D: IN VITRO CELL ATTACHMENT AND PROLIFERATION ON
CP5 COMPOSITE MICROSPHERES
The cytocompatibility of CP5 composite microspheres was evaluated using a
human osteosarcoma cell line (Saos-2, ATCC® Number: HTB-85™). The cell
attachment and growth study using Saos-2 cells was conducted in complete growth
medium composed of McCoy’s 5A Medium + 15% FBS + 1x AB/AM. Each treatment
group was gamma sterilized prior to starting the study.
As previously describe, 100 microspheres of CP5 were placed in glass culture
tubes, 13x100mm with screw cap (PYREX® Laboratory Glassware, CORNING, MA,
USA). 5mL of complete growth medium with cell concentration of 106 cells/mL was
added to each sample and gently agitated every 15 mins for four hours to ensure that the
microspheres were evenly coated. After four hours, the supernatant from each sample
was gently decanted and the number of cells was counted using a Z2 Coulter® Particle
Count and Size Analyzer (Beckman Coulter, Inc., USA) to determine the percentage of
cells attached to the surface of CP5 composite microspheres. The data were reported as
percent cell attachment ± standard deviation.
To CP5 samples, 2mL complete growth medium was added and replenished every
48 hours. Samples were evaluated at days 1, 3, 5 and 7 using the CellTiter-Glo®
Luminescent Cell Viability Assay (Promega, Wisconsin, USA) to determine the growth
of cells on CP5 based on quantification of the ATP present via the luciferase-luciferin
reaction. The data were reported as cell number/microsphere ± standard deviation.
Additionally, at each time point, CP5 samples were evaluated using a LIVE⁄DEAD®
Viability⁄Cytotoxicity Kit for mammalian cells (Invitrogen Corporation, California, USA)
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to determine the viability of cells based on plasma membrane integrity and esterase
activity of the cells.
For cellular attachment, one-way ANOVA analysis revealed that there was a
difference in cellular attachment between the different composite CTS-PLGA
microspheres (p = 0.035). However, post-hoc analysis showed that there were no
significant differences between CP0 and CP5; CP5 had a 32.7% ± 3.4% cell attachment
as compared to 23.1% ± 7.7% cell attachment seen for CP0 (Table 1).

Table 1. Percent Saos-2 cell attachment on CP5 compared with other composite
Chitosan-PLGA microspheres and plain CTS microspheres
Composite
Cell attachment
CTS-PLGA formulation
(%)
CP5

32.7 ± 3.4

CP0

23.1 ± 7.7

CP25

35.3 ± 5.5

CP50

30.2 ± 4.3

For proliferation, the results of the one-way ANOVA analysis revealed that there
were no differences in cellular growth on CP5 over time (p = 0.089) (Figure 5).
LIVE/DEAD images of CP5 composite microspheres were taken using a Nikon
ECLIPSE TE300 microscope with BIOQUANT OSTEO II software (Figure 6).
Qualitatively, it was observed that the number of cells/microsphere increases between
days 3 and 5. However, no difference in the number of cells/microsphere is seen between
days 1 and 3, and days 5 and 7.
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Figure 5. Proliferation of human osteosarcoma epithelial cell line, Saos-2, on CP5,
CTS microspheres with 5wt% PLGA, over a 7 day period evaluated using the
CellTiter-Glo® Luminescent Cell Viability Assay (n=4). No significant differences
were seen over the 7 day cell culture period (p = 0.089).
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Figure 6. Proliferation of human osteosarcoma epithelial cell line, Saos-2, on CP5,
CTS microspheres with 5wt% PLGA, over a 7 day period evaluated using
LIVE/DEAD® Viability⁄Cytotoxicity Kit for mammalian cells. The number of
cells/microsphere appears to increase between days 3 and 5 and remains constant
between days 1 and 3, and days 5 and 7.
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